NCT06126237View on ClinicalTrials.gov

A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

CM313 injection

CM313, subcutaneous injection

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT06126237 - A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter